Meeting News

Tumor-Infiltrating Lymphocytes ‘Capable of Destroying the Last Cancer Cell’

Cell Therapy Next, July 2019
Nearly a quarter of patients, 23.7%, treated with adoptive cell transfer tumor-infiltrating lymphocytes for metastatic melanoma have experienced…

Clinical Trials Snapshot

T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation

Cell Therapy Next, July 2019
Phase I dose-escalation trial evaluating the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV…

Clinical Trials Snapshot

Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Cell Therapy Next, July 2019
Phase 2, prospective, multicenter, single-arm, open-label, interventional trial evaluating adoptive cell therapy with autologous tumor infiltrating…

Clinical Trials Update

Specific Peptide-Enhanced Affinity Receptor T cells for Hepatocellular Carcinoma

Cell Therapy Next, July 2019
AFPc³³²T in Advanced HCC is a phase 1, open-label, first-in-human clinical trial to evaluate the safety and anti-tumor activity of…

Clinical Trials Snapshot

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Cell Therapy Next, July 2019
Phase 1 trial evaluating the safety, side effects, and benefits of tumor-infiltrating lymphocytes when they are given with the drug nivolumab.

Trend Watch

New Trial Uses Bispecific CAR T-Cell Therapy to Target Pediatric ALL

Cell Therapy Next, July 2019
Children’s National Health System in Washington, D.C., announced that it will be the second location to enroll patients in a pediatric trial…

In the JournalsPerspective

Neurotoxicity Affects Nearly Half of Patients Receiving CAR T-cell Therapy

Cell Therapy Next, July 2019
New data revealed that 48% of patients who received chimeric antigen receptor T-cell therapy for cancer treatment experienced neurological toxicity…

Guidelines

NCCN Releases Inaugural Pediatric ALL Clinical Practice Guidelines

Cell Therapy Next, July 2019
The National Comprehensive Cancer Network recently released its first clinical practice guidelines for children with acute lymphoblastic leukemia…

Clinical Trials Snapshot

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Cell Therapy Next, July 2019
Phase 2 trial evaluating whether specifically selected tumor-fighting cells can cause digestive tract, urothelial, breast, or ovarian/endometrial…

Clinical Trials Snapshot

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Cell Therapy Next, July 2019
Phase I/II trial evaluating how well genetically modified therapeutic autologous lymphocytes followed by aldesleukin work in treating patients with…

Cover Story

Driving Killer CARs into Cancer

Cell Therapy Next, July 2019
Automobile pioneer Henry Ford once said of his best-selling Model T, “Any customer can have a car painted any color that he wants so long as…

Clinical Trials Snapshot

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

Cell Therapy Next, July 2019
Phase 2 trial evaluating the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous…

In the JournalsPerspective

CAR T-cell therapies may be cost-effective for patients with lymphoma subtype

July 23, 2019
The chimeric antigen receptor T-cell therapies axicabtagene ciloleucel and tisagenlecleucel may meet a cost-effectiveness threshold of less than…

In the Journals

CD19-specific CAR T-cell therapy feasible for aggressive non-Hodgkin lymphoma

July 23, 2019
CD19-specific chimeric antigen receptor T-cell therapy after high-dose chemotherapy and autologous stem cell transplant appeared feasible for…

Meeting NewsVideo

VIDEO: Initial results of ZUMA-3 trial ‘highly encouraging’ for relapsed, refractory leukemia

July 21, 2019
CHICAGO — Bijal D. Shah, MD, associate professor in the department of malignant hematology at Moffitt Cancer Center, spoke with HemOnc

Meeting News

Nonengineered T cells may be ‘clinically meaningful’ for pancreatic cancer

July 19, 2019
More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell…

Feature

Intersection of radiotherapy, immunotherapy guides Penn’s new cancer research center

July 18, 2019
The Abramson Cancer Center at the University of Pennsylvania has been awarded a $12 million grant from the Mark Foundation for Cancer Research to…

Meeting News

ASH announces award recipients

July 15, 2019
Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition…

Meeting NewsVideo

VIDEO: Early steroids may reduce severe side effects among patients who receive CAR T-cell therapy

July 13, 2019
CHICAGO — Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today at ASCO Annual…

Feature

Natural Killer Cell Therapy: A Look Inside a ‘Living Drug in a Bottle’

July 9, 2019
The ability to harness the human immune system and use it to fight cancer remains a significant area of focused research and is likely to remain so…